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Abstract
Background. Chronic red blood cell transfusion is the 
first-line treatment for severe forms of thalassaemia. This 
therapy is, however, hampered by a number of adverse 
effects, including red blood cell alloimmunisation. The 
aim of this systematic review was to collect the current 
literature data on erythrocyte alloimmunisation.
Materials and methods. We performed a systematic 
search of the literature which identified 41 cohort studies 
involving 9,256 patients.
Results. The prevalence of erythrocyte alloimmunisation 
was 11.4% (95% CI: 9.3-13.9%) with a higher rate of 
alloimmunisation against antigens of the Rh (52.4%) 
and Kell (25.6%) systems. Overall, alloantibodies 
against antigens belonging to the Rh and Kell systems 
accounted for 78% of the cases. A higher prevalence of 
red blood cell alloimmunisation was found in patients 
with thalassaemia intermedia compared to that among 
patients with thalassaemia major (15.5 vs 12.8%).
Discussion. Matching transfusion-dependent 
thalassaemia patients and red blood cell units for Rh 
and Kell antigens should be able to reduce the risk of 
red blood cell alloimmunisation by about 80%. 
Keywords: thalassaemia, alloimmunisation, red blood 
cells, transfusion, complications.
Introduction
Thalassaemia, a congenital haemolytic disorder 
caused by a partial or complete defect in the synthesis 
of α- or β-globin chains, is one of the major health issues 
worldwide, considering that every year 60,000 babies are 
born with severe forms of thalassaemia1. The primary 
therapy for thalassaemia major is lifelong transfusion of 
red blood cells (RBC), which has the aim of suppressing 
ineffective erythropoiesis and improving the growth and 
development of affected children2. However, although 
this treatment is life-saving, it is encumbered by a 
number of complications, including haemosiderosis, 
transfusion reactions, infections (potentially caused 
also by emerging or re-emerging infectious disease 
agents3,4, as the residual risk of transfusion-transmitted 
infections has consistently declined over time5), and 
alloimmunisation6-11. In particular, alloimmunisation 
is a challenging occurrence which increases the 
risk of delayed haemolytic transfusion reactions, 
complicates cross-matching and contributes to a delay 
in the identification and provision of compatible RBC 
transfusions10,11. Transfusion therapy may also be 
required by patients with thalassaemia intermedia in 
particular circumstances (growth failure, extramedullary 
haematopoiesis, pregnancy, infections, operations) so 
that a consistent proportion of such patients are at risk 
of developing transfusion-associated complications, 
including alloimmunisation12.
The purpose of this systematic review is to summarise 
the current literature on erythrocyte alloimmunisation in 
patients with transfusion-dependent thalassaemia, with 
the aim of improving our knowledge on the associated 
risk factors and optimising the approach to patients' 
transfusion therapy.
Materials and methods
Search strategy 
A computer-assisted literature search of the 
MEDLINE (through PUBMED), EMBASE, SCOPUS, 
OVID and Cochrane Library electronic databases was 
performed (latest search August 30, 2018) to identify 
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studies on RBC alloimmunisation in patients with 
transfusion-dependent thalassaemia. A combination 
of the following text words was used to maximise 
the specificity and sensitivity of the search: "red 
blood cells", "erythrocyte", "alloimmunization", 
"alloantibodies", "reactions", "thalassemia major", 
"thalassemia intermedia", "beta thalassemia", "β 
thalassemia", "transfusion", "transfusion-dependent", 
"patients". In addition, we checked the reference lists of 
the most relevant items (original studies and reviews) in 
order to identify potentially eligible studies not captured 
by the initial literature search. 
Study selection and inclusion criteria
Studies were selected independently by two reviewers 
(MF and MC), with disagreements resolved through 
discussion and on the basis of the opinion of a third reviewer 
(GM). Assessment of the eligibility of studies was based on 
the title or abstract and on the full text, if required. Articles 
were eligible if they reported erythrocyte alloimmunisation 
in transfusion-dependent thalassaemia patients (i.e., patients 
with thalassaemia major or thalassaemia intermedia) in 
either the title or the abstract. Other required inclusion 
criteria were that the article be: (i) original, (ii) randomised, 
cohort, cross-sectional or case-control, (iii) retrospective or 
prospective, and (iv) published in full in English in the last 
20 years (1998-2018).
Data extraction
For each study included in the systematic review13-53, 
the following data were extracted independently by two 
reviewers (MF and MC): first author, year of publication, 
origin of the population studied, study design, sample 
size and disease type, median age and range, rate and 
type of RBC alloantibodies detected, type of test used 
for alloantibody detection, transfusion protocol and 
evaluated variables (RBC phenotype matching, sex, 
age at enrolment, age at first transfusion, years of 
transfusions, RBC units received, splenectomy, RBC 
leucoreduction) with the main results of the studies. 
Disagreement was resolved by consensus and by the 
opinion of a third reviewer (GM), if necessary.
Assessment of risk of bias in the included studies
Since no randomised controlled trials were found for 
this systematic review, we assessed the methodological 
quality of the observational studies following the 
recommendations from the Cochrane Handbook for 
Systematic Reviews of Interventions on assessing 
the quality of non-randomised studies54. We used the 
Newcastle-Ottawa quality assessment scale  (NOS) to 
assess the quality of cohort studies55. 
The methodological quality of cohort studies is 
assessed by examining selection (four questions relating 
to the representativeness of the cohort, selection of 
the unexposed cohort, ascertainment of exposure and 
demonstration that the outcome of interest was not 
present at the start of the study), comparability (exposed 
and unexposed individuals must be matched in the 
design and/or confounders must be adjusted for in the 
analysis) and outcome (three questions relating to the 
assessment of outcome, follow up long enough for 
outcomes to occur and losses to follow up). 
These assessments were performed independently in 
duplicate (MC, MF) and a third reviewer (GM) resolved 
any disagreements to reach consensus. Using the NOS, 
a study can be awarded a maximum of four stars for 
selection, a maximum of two stars for comparability, 
and a maximum of three stars for outcome (Online 
Supplementary Content, Table SI).
Statistical analysis
Qualitative data are presented as numbers and 
percentages, while quantitative data are expressed 
statistically in frequencies and percentages. A mean 
prevalence of RBC alloantibodies was estimated 
by meta-analysis of the proportions method. This 
method is based on meta-analytical pooling of the 
logit-transformed prevalences at a study level. These 
are used to produce summary measures. The meta-
analytical methods used were: the inverse variance 
method; DerSimonian-Laird estimator for tau2; logit 
transformation; Clopper-Pearson confidence interval 
for individual studies; and a continuity correction of 
0.5 in studies with zero cell frequencies. Both fixed 
effects and random effects models were used. The 
heterogeneity between studies was assessed by the 
heterogeneity χ2 test (Cochran's Q), the I2 statistics, 
and the DerSimonian-Laird estimate of between-
study variance (τ2). When the size of the population 
affected by thalassaemia major or thalassaemia 
intermedia clinical variants was reported along with 
the alloantibody prevalence, the relevant information 
was used to perform subgroup analyses. The random 
effects model is reported as it is preferred in subgroup 
meta-analyses, or when heterogeneity tests are 
significant. All calculations were done using R-3.5.1 
for windows.
Results
Literature search and characteristics of the studies
In total, 478 articles were identified through the 
initial electronic and manual searches (Figure 1). 
Three hundred and fifty-two of them were excluded 
because they focused on topics outside the scope of 
this systematic review. Thus, 126 potentially relevant 
articles were selected and the next screening led to the 
exclusion of 85 of these (reviews, duplicates, studies 
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not evaluating patients with transfusion-dependent 
thalassaemia, studies containing no informative data). 
Finally, 41 studies13-53 were included in the systematic 
review (see Table I for the main characteristics and 
results of the studies included). The studies contained 
data from 9,256 individuals (children and adults) from 
different countries and originated in India (n=12), Iran 
(n=6), Egypt (n=6), Pakistan (n=3), Oman (n=3), Taiwan 
(n=2), Asia (n=2) and the USA, Malaysia, Tunisia, Hong 
Kong, Turkey, Albania, Kuwait (each with 1 study) 
(Table I). No studies conducted in European countries 
were included in this systematic review.
All the studies were classified as cohort 
studies. The design was retrospective in 11 
studies13,15,27,28,32,35-37,50-52 and prospective in 1714,17,20,24-
26,29,31,34,38,39,41,43,46-49. Thirteen studies16,18,19,21-23,30,33,40,42,44,45,53 
in which the investigator sampled a source population 
cross-sectionally and then retrospectively assessed subjects' 
histories of exposures and outcomes over a specified time 
period were defined as cross-sectional cohort studies56.
The sample size of the included studies ranged from 30 
patients in the study by Wang and colleagues16 to 835 patients 
in the study by Azarkeivan and colleagues25. Transfusion-
dependent thalassaemia was β-thalassaemia major in the 
majority of cases (n=4,829); patients with thalassaemia 
intermedia (n=491), α-thalassaemia syndromes as well 
as haemoglobin E/β thalassaemia (n=148) and otherwise 
undefined cases (n=3,788) were also included.
Bias assessment
We present the results of the NOS in the Online 
Supplementary Content, Table SI. The quality of 
cohort studies was assessed by examining selection, 
comparability and outcome. Of the 41 cohort studies 
included, all achieved the maximum four stars for 
selection, and the maximum three stars for outcome; for 
comparability, 39 studies achieved the maximum two 
stars, but two studies merited only one star because they 
did not control for confounders16,23.
Frequency of erythrocyte alloimmunisation
Online Supplementary Table SII reports the 
detailed analysis of RBC alloantibodies for each study. 
The great majority of the studies included used high 
sensitivity agglutination microcolumn assays (Online 
Supplementary Content, Table SIII). The prevalence 
Figure 1 - Flow chart of the selection of the studies.
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of alloantibodies in the thalassaemia patients, 
without distinguishing between the clinical variants, 
is depicted in Figure 2. As stated above, 41 studies 
were included. The random effects model resulted in a 
mean prevalence of 0.1137 (95% CI: 0.0928; 0.1386). 
The heterogeneity was substantial: Cochran's Q 
was 427.80, with degrees of freedom (d.o.f.)=40 
(p<0.0001), τ2=0.4613, I2=90.6% (88.3%; 92.6%). 
The variation of erythrocyte alloimmunisation ranged 
from 2.9% (Sadeghian et al.19) to 37.0% (Wang et 
al.16). Taking into account all selected studies, a 
higher rate of alloimmunisation against antigens of 
the Rh system (52.4%), especially against E antigen 
(22.0%), was observed, showing that these antigens 
are among the most immunogenic. Alloantibodies 
against D, C, c and e antigens accounted for 6.9%, 
5.5%, 5.5% and 1.3% of the cases, respectively. 
The second highest rate was found for alloantibody 
antigens of the Kell system (25.6%), especially 
against K antigen (22.5%), followed by the Kidd 
system (3.9%) and the MNS system (2.4%) (Online 
Supplementary Content, Table SII). Notably, 
alloimmunisation against antigens of the Rh and 
Kell systems accounted for 78% of the total cases. It 
should be noted that 9.4% of alloimmunised patients 
had antibodies directed against more than one RBC 
antigen (mostly, alloantibodies against antigens of the 
Rh and Kell systems). Four studies27,28,35,39 reported 
only the frequency per single antigen without a 
description of the presence of more than one antigen 
in the same subject.  
The comparison of the prevalence of erythrocyte 
alloantibodies in patients with thalassaemia major (total 
25 studies evaluated) and thalassaemia intermedia (total 
8 studies evaluated) is presented in Figure 3 and Table 
II. In patients with thalassaemia major, Q was 212.1, τ2 
0.4583, I2 88.7%, whereas in those with thalassaemia 
intermedia, Q was 24.59, τ2 0.4134, and I2 71.5%. In the 
aggregate set of patients with either thalassaemia major 
or thalassaemia intermedia, Q was 239.1, τ2 0.4437, and 
I2 86.6%. The results of the test for subgroup differences 
(random effects model) were: Q=1.95, d.o.f.=1, 
p=0.1629 (not significant). Thus, the prevalence of 
alloantibodies in thalassaemia major and thalassaemia 
intermedia did not appear to differ significantly. The 
rate of erythrocyte alloimmunisation in patients with 
thalassaemia major ranged from 2.7% (Bhuva et al.49) 
to 30.0% (Ameen et al.14) and from 0% (Dogra et al.40) 
to 38.1% (Saied et al.27) in patients with thalassaemia 
intermedia (Online Supplementary Table SIV). 
Analysis of risk factors associated with erythrocyte 
alloimmunisation
The main risk factors for RBC alloimunisation 
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that emerged from the analysis of the studies included 
(Table II) were: age25,27,29,52, female gender19,34,48, 
splenectomy13,20,26,29,35,42,48, first transfusion before 2-3 
years of age22,33,37,48, and RBC units received/duration 
of blood transfusion/transfusion frequency18,26,27,29,35,39,52. 
By contrast, increased antigen matching for Rh and 
Kell and the use of leucoreduced RBC were found 
Figure 2 - Forest plot of the prevalence of red blood cell alloantibodies in patients with 
thalassaemia.
 CI: confidence intervals.
Table II - Comparison of the prevalence of erythrocyte alloimmunisation between patients 
with thalassaemia major and thalassaemia intermedia.
Subgroup Model N. of studies Mean proportion 95% C.I.
TM Random effects 25 0.1012 0.0773 0.1313
TI Random effects 8 0.1497 0.0918 0.2345
All Random effects 33 0.1100 0.0871 0.1380
Studies distinguishing the clinical variants, thalassaemia major (TM) and thalassaemia intermedia (TI).The 
mean proportion (prevalence) of alloantibodies is reported for patients with TM and TI with 95% confidence intervals 
(C.I.). The same indexes are reported on the aggregate (all) set of studies.
to have a protective effect against alloantibody 
development13,14,25,27,35,43,45,47. 
A meta-analytical approach to weigh the risk of 
RBC alloimmunisation associated with each factor 
was not possible because of the clinical heterogeneity 
and inconsistency of reporting among the different 
studies.
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or simply by chance. In the current systematic review, 
the statistical heterogeneity was substantial; this was 
addressed by using a random effects model. A random 
effects model allows more flexibility, assuming 
that there may be other factors influencing the data 
than error or chance, within and between studies. 
Beside the statistical heterogeneity, there was clinical 
and methodological heterogeneity in the studies 
included in the review. Differences in study designs 
and methodological quality (risk of bias) represent 
methodological heterogeneity. All the studies included 
in this review were classified as cohort studies, although 
the design of the studies varied. There were prospective, 
retrospective and cross-sectional cohorts. However, 
our assessment of bias using the NOS shows that the 
quality of the included studies was high. There was 
Figure 3 - Forest plots of the prevalence of red blood cell alloantibodies in patients with 
thalassaemia major (TM) or thalassaemia intermedia (TI).
 CI: confidence intervals.
Discussion 
To our knowledge, this is the first published systematic 
review on the prevalence of RBC alloimmunisation in 
patients with transfusion-dependent thalassaemia. 
After the identification of 41 eligible cohort studies 
involving 9,256 thalassaemia patients, we determined 
a prevalence of erythrocyte alloimmunisation of 11.4%. 
The wide variation in the rate of RBC alloimmunisation 
(2.9 to 37%) observed among the different studies 
probably reflects the heterogeneity of the studies, 
which is common in reviews addressing prevalence and 
incidence data. There are three types of heterogeneity: 
clinical, methodological, and statistical57. Statistical 
heterogeneity is the variation of effects sizes between 
studies. Statistical heterogeneity may arise because of 
clinical heterogeneity, methodological heterogeneity, 
All rights reserved - For personal use only 
No other use without premission
© 
SIM
TIP
RO
 Sr
l
13
Blood Transfus 2019; 17: 4-15  DOI 10.2450/2019.0229-18
Red blood cell alloantibodies in thalassaemia
also clinical heterogeneity in the studies considered 
in the analysis related to specific covariates (e.g., age, 
gender, ethnicity), transfusion policy (including the 
use of non-leucoreduced RBC units and the degree of 
antigen-matching techniques), different methods of 
antibody identification, and heterogeneity of the donor 
and the recipient populations. Unfortunately, due to 
limitations and inconsistencies in reporting alloantibody 
prevalences according to these covariates, we could not 
perform subgroup analyses or meta-regressions for all 
the relevant covariates. However, our subgroup analysis 
of clinical variants showed that the prevalences of 
alloantibodies in thalassaemia major and thalassaemia 
intermedia did not differ significantly.
It has been consistently reported that the ethnic 
correlation between donors and recipients influences 
the frequency of erythrocyte alloimmunisation in both 
thalassaemia and sickle cell anaemia patients58. Lower 
rates of RBC alloimmunisation were reported in studies 
with more homogeneous donor and patient populations, 
while higher rates were observed in studies with ethnic/
racial disparity between donors and recipients. For 
example, in the study by Abdelrazik and colleagues48, 
the relatively low rate of alloimmunisation (8%) was 
attributed to the fact that blood donors and thalassaemic 
patients were from the same ethnic Egyptian group.
Among the other risk factors associated with 
RBC alloimmunisation in patients with transfusion-
dependent thalassaemia, splenectomy was that 
most frequently reported. For instance, Singer and 
colleagues13 reported that patients who underwent 
splenectomy had a higher rate of alloimmunisation 
compared to non-splenectomised patients (36 vs 
12.8%). In multivariate analysis, Thompson and co-
workers26 found that splenectomy was an independent 
risk factor for alloimmunisation. The mechanism by 
which removal of the spleen increases alloantibody 
formation is unclear. One possible explanation is that 
the absence of the spleen may further enhance the 
immune response to infused foreign blood antigens that 
are not effectively filtered. Other studies, however, did 
not find such an association37,52. In any case, although 
frequently performed in the past, the currently lower 
tendency to perform splenectomy in transfusion-
dependent thalassaemia patients might mitigate such 
risk.
Other important risk factors for RBC alloimmunisation 
that emerged from our systematic analysis of the 
literature were the duration of transfusions and the age 
at the start of transfusion therapy, with older patients 
being at increased risk. While the former finding is 
obviously related to the amount of exposure to RBC 
antigens during the years of blood transfusions1, the 
latter is quite intriguing. Some authors have in fact 
reported a lower rate of alloimmunisation in patients 
who began transfusion before 2-3 years of age22,33. The 
still immature immune system of young patients could 
be responsible for a lower risk of alloimmunisation 
by creating a kind of immunotolerance. While the 
early institution of transfusion therapy after diagnosis 
could be an interesting approach to minimise the risk 
of alloimmunisation risk, on the other hand it could 
expose patients with thalassaemia to an increased 
risk of other transfusion-related complications. 
An unresolved issue regards the different risk of RBC 
alloimmunisation in transfusion-dependent patients with 
thalassaemia major or thalassaemia intermedia. Various 
studies found a higher percentage of RBC alloantibodies 
among patients with thalassaemia intermedia than 
among those with thalassaemia major20,25,48. The results 
of our systematic review confirm this trend (Table II): 
although the difference was not statistically significant, 
we observed a higher prevalence of alloantibodies in 
patients with thalassaemia intermedia. While patients 
with thalassaemia major usually start RBC transfusions 
earlier than patients with thalassaemia intermedia and 
thus could benefit from the protective effect of the 
younger age reported above, this finding could also 
reflect differences in transfusion policies between the 
two types of thalassaemia. Indeed, it is conceivable that 
patients with thalassaemia intermedia, having lower and 
less regular transfusion requirements, could be transfused 
more frequently with non-extended phenotype matched 
RBC units than are patients with thalassaemia major29. 
On the other hand, the large differences in sample sizes 
among the two cohorts of patients evaluated (4,829 
patients with thalassaemia major vs 491 patients with 
thalassaemia intermedia) could represent an important 
bias for the subgroup analysis of the results.
No definitive association between female gender and 
alloimmunisation risk could be found because of the 
conflicting results reported from the different studies 
included in this systematic analysis.
Finally, in this systematic review the most frequent 
antibodies identified in patients with transfusion-
dependent thalassaemia were directed against Rh and 
Kell systems, accounting for 78% of all cases. This 
means that matching RBC units for these antigens will 
reduce the risk of RBC alloimunisation by about 80% 
in such patients. With the aim of risk minimisation, 
we therefore recommend, in accordance with the main 
standard guidelines59-62, the implementation of an early 
diagnosis of thalassaemia with the determination of 
baseline extended RBC phenotype and the provision of 
RBC units matched for Rh and Kell antigens.
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